CareLit Fachartikel

Dengue vaccine development: status and future

Wilder-Smith, A. · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · 2019 · Heft 11 · S. 40 bis 44

Dokument
342741
CareLit-ID
Jahr
2019
Publikation
PDF
nein
Metadaten
DOI
–
zitierfähig

Bibliografische Angaben

Zeitschrift
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
Autor:innen
Wilder-Smith, A.
Ausgabe
Heft 11 / 2019
Jahrgang 62
Seiten
40 bis 44
Erschienen: 2019-11-29 18:54:26
ISSN
1437-1588
DOI
–

Zusammenfassung

Dengue, the most common arbovirus, represents an increasingly significant cause of morbidity worldwide, including in travelers. After decades of research, the first dengue vaccine was licensed in 2015: CYD-TDV, a tetravalent live attenuated vaccine with a yellow fever vaccine backbone. Recent analyses have shown that vaccine performance is dependent on serostatus. In those who have had a previous dengue infection, i.e., who are seropositive, the efficacy is high and the vaccine is safe. However, in seronegative vaccinees, approximately 3 years after vaccination the vaccine increases the risk of developing severe…

Schlagworte

Gesundheit Pflege Dengue After Infektion Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz